Skip to main content
Boule Diagnostics logo

Boule Diagnostics — Investor Relations & Filings

Ticker · BOUL ISIN · SE0011231158 LEI · 213800IK1TGY858TKZ45 ST Manufacturing
Open in API
Filings indexed 227 across all filing types
Latest filing 2026-06-18 Board/Management Inform…
Country SE Sweden
Listing ST BOUL

About Boule Diagnostics

https://boule.com/

Boule Diagnostics is a global provider of diagnostic solutions specializing in hematology. The company develops, manufactures, and markets systems and consumables for blood diagnostics, including hematology analyzers, clinical chemistry analyzers, and associated reagents, controls, and calibrators. Its products are tailored for decentralized healthcare settings in both the human and veterinary markets, such as smaller laboratories and clinics. The company aims to enhance global healthcare access by providing high-quality instruments that deliver timely and accurate blood test results.

Recent filings

Filing Released Lang Actions
Boule Diagnostics utser ny verkställande direktör
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new CEO for Boule Diagnostics, detailing Johan Folkunger's professional background and quotes from relevant company representatives. There is no financial data, report contents, or detailed regulatory compliance information. The document fits the category of a Board/Management Information announcement, as it concerns a change in senior management (CEO appointment). The document length is relatively short (3183 characters), which is consistent with an announcement rather than a full report. There are no elements of financial results, voting results, audit details, or other specific filings. Therefore, the classification is Board/Management Information (MANG).
2026-06-18 Swedish
Boule Diagnostics appoints new Chief Executive Officer
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of a new Chief Executive Officer at Boule Diagnostics. It includes biographical information about the incoming CEO, comments from the Chair of the Board, and contact information. There are no financial statements or analyses, no voting results, no details on governance practices beyond the appointment, and no mention of report publications or filings. The document length is 3118 characters, which is short and typical for an announcement. This fits the category of Board/Management Information (MANG), as it announces a change in the company's senior management.
2026-06-18 English
Kommuniké från Boule Diagnostics årsstämma den 13 maj 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a press release summarizing the resolutions and voting outcomes from Boule Diagnostics’ Annual General Meeting held on May 13, 2026. It lists the approved balance sheets, discharge from liability, board and auditor elections, remuneration, and authorizations—all official shareholder vote results. This fits the Definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-13 Swedish
Bulletin from the Annual General Meeting May 13, 2026 in Boule Diagnostics
Declaration of Voting Results & Voting Rights Announcements Classification · 89% confidence The document is a press release summarizing the resolutions passed at the company’s Annual General Meeting (AGM) on May 13, 2026 (adoption of financial statements, dividend decision, board elections, discharge of liability, auditor appointment, authorizations, etc.). It does not contain a full annual report or financial data itself, nor is it a presentation slide deck. It is an official notice of shareholder voting outcomes at the AGM. Therefore, it fits the definition of Declaration of Voting Results & Voting Rights (DVA).
2026-05-13 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled “Delårsrapport Q1 2026” and provides a full interim/quarterly financial report for the period January–March 2026, including detailed income statements, balance sheet figures, segment data, management commentary, and cash flow analysis. It is comprehensive rather than a brief earnings release or simply an announcement of publication. Therefore, it fits the definition of an Interim / Quarterly Report. Q1 2026
2026-04-28 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 98% confidence The document is titled “Interim Report Q1 2026” and provides comprehensive financial statements and substantive analysis for the quarter January–March 2026, including net sales, profit, cash flow, balance sheet items, CEO comments, and strategic commentary. It clearly represents a quarterly financial report rather than a simple announcement or press release. Therefore, it matches the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-04-28 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.